Mylan Weighs In On Coronavirus Drug Shortage Concerns
Executive Summary
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
You may also be interested in...
US FDA Requests Frequent Updates On Supply Chain Disruptions In COVID-19 Era
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.
Variety Of Impacts COVID-19 Poses For Biopharma Reflected In Earnings Calls
Several firms reporting quarterly earnings this week discussed how the outbreak is affecting supply chains, drug launches and clinical trials.
Coronavirus May Boost Policy Efforts To Enhance US Drug, Medical Supply Production
Sen. Alexander says Congress should consider options to alleviate US dependence on other countries for drug and medical supply production once the outbreak subsides.